This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (53)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Experience of the Optic Neuritis Treatment Trial

The Optic Neuritis Study Group

Arch Ophthalmol. 1997;115(12):1545-1552.

Abstract
Objective
To assess the 5-year visual course, including the incidence of recurrent optic neuritis, in 454 patients enrolled in the Optic Neuritis Treatment Trial.

Methods
Five-year follow-up vision testing, which included measures of visual acuity, contrast sensitivity, visual field, and color vision, was completed for 397 (87%) of the 454 patients.

Results
Visual function test results in the eyes that experienced optic neuritis at study enrollment (affected eyes) were normal or only slightly abnormal after 5 years in most patients; the results did not significantly differ by treatment group (P=.37 for visual acuity). The visual acuity in the affected eyes was 20/25 or better in 87%, 20/25 to 20/40 in 7%, 20/50 to 20/190 in 3%, and 20/200 or worse in 3%. The recurrence of optic neuritis in either eye occurred in 28% of the patients and was more frequent in patients with multiple sclerosis (P=.001) and in patients without multiple sclerosis who were in the prednisone treatment group (P=.004). Most eyes with a recurrence retained normal or almost normal visual function.

Conclusions
Most patients retained good to excellent vision in the 5 years following an attack of optic neuritis, even if the optic neuritis recurred. Recurrences were more frequent in patients with multiple sclerosis and in those treated with oral prednisone alone. The completion of the 5-year follow-up by the Optic Neuritis Treatment Trial cohort has not altered our management recommendations based on the results we reported earlier.

Footnotes
Members of the writing team, who signed authorship responsibility, financial disclosure, and copyright transfer statements for the group are as follows: Roy W. Beck, MD, PhD, Jonathan D. Trobe, MD, and Pamela S. Moke, MSPH (primary authors); Michael C. Brodsky, MD, Edward G. Buckley, MD, Georgia A. Chrousos, MD, James A. Goodwin, MD,John R. Guy, MD, Barrett Katz, MD, David I. Kaufman, DO, John L. Keltner, MD, Mark J. Kupersmith, MD, Neil R. Miller, MD, Silvia Orengo-Nania, MD, peter J. Savino, MD, William T. Shults, MD, Craig H. Smith, MD, H. Stanley Thompson, MD, and Michael Wall, MD (other authors). A complete list of the members of the Optic Neuritis Study Group appears on page 1547.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography
Costello et al.
Mult Scler 2008;14:893-905.
ABSTRACT  

Treatment of Acute Optic Neuritis: A Summary of Findings From the Optic Neuritis Treatment Trial
Beck and Gal
Arch Ophthalmol 2008;126:994-995.
FULL TEXT  

The Optic Neuritis Treatment Trial: A Definitive Answer and Profound Impact With Unexpected Results
Volpe
Arch Ophthalmol 2008;126:996-999.
FULL TEXT  

Multiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-up
The Optic Neuritis Study Group
Arch Neurol 2008;65:727-732.
ABSTRACT | FULL TEXT  

Optic Neuritis Associated With Chikungunya Virus Infection in South India
Mittal et al.
Arch Ophthalmol 2007;125:1381-1386.
ABSTRACT | FULL TEXT  

Clinical practice. Optic neuritis.
Balcer
NEJM 2006;354:1273-1280.
FULL TEXT  

Long-term Brain Magnetic Resonance Imaging Changes After Optic Neuritis in Patients Without Clinically Definite Multiple Sclerosis
Optic Neuritis Study Group
Arch Neurol 2004;61:1538-1541.
ABSTRACT | FULL TEXT  

Neurologic Impairment 10 Years After Optic Neuritis
Optic Neuritis Study Group
Arch Neurol 2004;61:1386-1389.
ABSTRACT | FULL TEXT  

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite
Balcer et al.
Neurology 2003;61:1367-1373.
ABSTRACT | FULL TEXT  

High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis: Experience of the Optic Neuritis Treatment Trial
Optic Neuritis Study Group*
Arch Ophthalmol 2003;121:944-949.
ABSTRACT | FULL TEXT  

High dose intravenous steroid therapy for severe posterior segment uveitis in Behcet's disease
Toker et al.
Br J Ophthalmol 2002;86:521-523.
ABSTRACT | FULL TEXT  

Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England
Ghosh et al.
J. Neurol. Neurosurg. Psychiatry 2002;72:119-121.
ABSTRACT | FULL TEXT  

Frequency Doubling Perimetry in Resolved Optic Neuritis
Fujimoto and Adachi-Usami
IOVS 2000;41:2558-2560.
ABSTRACT | FULL TEXT  

Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Kaufman et al.
Neurology 2000;54:2039-2044.
FULL TEXT  

New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis
Balcer et al.
Mult Scler 2000;6:163-171.
ABSTRACT  

The National Eye Institute Visual Function Questionnaire: Experience of the ONTT
Cole et al.
IOVS 2000;41:1017-1021.
ABSTRACT | FULL TEXT  

Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis
Guy et al.
Proc. Natl. Acad. Sci. USA 1998;95:13847-13852.
ABSTRACT | FULL TEXT